Glutamine is essential for maintaining the TCA cycle in cancer cells yet they undergo glutamine starvation in the core of tumors. Cancer stem cells (CSCs), responsible for tumor recurrence are often found in the nutrient limiting cores. Our study uncovers the molecular basis and cellular links between glutamine deprivation and stemness in the cancer cells. We showed that glutamine is dispensable for the survival of ovarian and colon cancer cells while it is required for their proliferation. Glutamine starvation leads to the metabolic reprogramming in tumor cells with enhanced glycolysis and unaltered oxidative phosphorylation. Production of reactive oxygen species (ROS) in glutamine limiting condition induces MAPK-ERK1/2 signaling pathway to phosphorylate dynamin-related protein-1(DRP1) at Ser616. Moreover, p-DRP1 promotes mitochondrial fragmentation and enhances numbers of CD44 and CD117/CD45 positive CSCs. Besides the established features of cancer stem cells, glutamine deprivation induces perinuclear localization of fragmented mitochondria and reduction in proliferation rate which are usually observed in CSCs. Treatment with glutaminase inhibitor (L-DON) mimics the effects of glutamine starvation without altering cell survival in in vitro as well as in in vivo model. Interestingly, the combinatorial treatment of L-DON with DRP1 inhibitor (MDiVi-1) reduces the stem cell population in tumor tissue in mouse model. Collectively our data suggest that glutamine deficiency in the core of tumors can increase the cancer stem cell population and the combination therapy with MDiVi-1 and L-DON is a useful approach to reduce CSCs population in tumor.
This is a preview of subscription content, access via your institution.
Buy single article
Instant access to the full article PDF.
Tax calculation will be finalised during checkout.
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
Tax calculation will be finalised during checkout.
Availability of data
Data are available on request from the corresponding author.
Mitra T, Prasad P, Mukherjee P et al (2018) Stemness and chemoresistance are imparted to the OC cells through TGFβ1 driven EMT. J Cell Biochem 119:5775–5787. https://doi.org/10.1002/jcb.26753
Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144:646–674. https://doi.org/10.1016/j.cell.2011.02.013
Pavlova NN, Thompson CB (2016) The Emerging hallmarks of cancer metabolism. Cell Metab 23:27–47. https://doi.org/10.1016/j.cmet.2015.12.006
Souba WW (1993) Glutamine and cancer. Ann Surg 218:715–728
Yang L, Achreja A, Yeung TL et al (2016) Targeting stromal glutamine synthetase in tumors disrupts tumor microenvironment-regulated cancer cell growth. Cell Metab 24:685–700. https://doi.org/10.1016/j.cmet.2016.10.011
Cluntun AA, Lukey MJ, Cerione RA, Locasale JW (2017) Glutamine metabolism in cancer: understanding the heterogeneity. Trends in Cancer 3:169–180. https://doi.org/10.1016/j.trecan.2017.01.005
Scalise M, Pochini L, Galluccio M et al (2017) Glutamine transport and mitochondrial metabolism in cancer cell growth. Front Oncol 7:1–9. https://doi.org/10.3389/fonc.2017.00306
Huang W, Choi W, Chen Y et al (2013) A proposed role for glutamine in cancer cell growth through acid resistance. Cell Res 23:724–727. https://doi.org/10.1038/cr.2013.15
Sabharwal SS, Schumacker PT (2014) Mitochondrial ROS in cancer: initiators, amplifiers or an Achilles’ heel? Nat Rev Cancer 14:709–721. https://doi.org/10.1038/nrc3803
Zhao J, Zhang J, Yu M et al (2013) Mitochondrial dynamics regulates migration and invasion of breast cancer cells. Oncogene 32:4814–4824. https://doi.org/10.1038/onc.2012.494
Al-Mehdi AB, Pastukh VM, Swiger BM et al (2012) Perinuclear mitochondrial clustering creates an oxidant-rich nuclear domain required for hypoxia-induced transcription. Sci Signal 5:1–10. https://doi.org/10.1126/scisignal.2002712
Cacace A, Sboarina M, Vazeille T, Sonveaux P (2017) Glutamine activates STAT3 to control cancer cell proliferation independently of glutamine metabolism. Oncogene 36:2074–2084. https://doi.org/10.1038/onc.2016.364
Yang L, Moss T, Mangala LS et al (2014) Metabolic shifts toward glutamine regulate tumor growth, invasion and bioenergetics in ovarian cancer. Mol Syst Biol 10:1–23. https://doi.org/10.1002/msb.20134892
Yuan L, Sheng X, Willson AK et al (2015) Glutamine promotes ovarian cancer cell proliferation through the mTOR/S6 pathway. Endocr Relat Cancer 22:577–591. https://doi.org/10.1530/ERC-15-0192
Choi Y, Park K (2018) Targeting glutamine metabolism for cancer treatment. Biomol Ther 26:19–28
Vaupel P, Kallinowski F, Okunieff P (1989) Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: a review. Cancer Res 49:6449–6465
Das N, Mandala A, Naaz S et al (2017) Melatonin protects against lipid-induced mitochondrial dysfunction in hepatocytes and inhibits stellate cell activation during hepatic fibrosis in mice. J Pineal Res 62:1–21. https://doi.org/10.1111/jpi.12404
Chowdhury SR, Ray U, Chatterjee BP, Roy SS (2017) Targeted apoptosis in ovarian cancer cells through mitochondrial dysfunction in response to Sambucus nigra agglutinin. Cell Death Dis 8:1–12. https://doi.org/10.1038/cddis.2017.77
Khan M, Biswas D, Ghosh M et al (2015) mTORC2 controls cancer cell survival by modulating gluconeogenesis. Cell Death Discov 1:1–12. https://doi.org/10.1038/cddiscovery.2015.16
Maftah A, Petit JM, Ratinaud MH, Julien R (1989) 10-N nonyl-acridine orange: a fluorescent probe which stains mitochondria independently of their energetic state. Biochem Biophys Res Commun 164:185–190. https://doi.org/10.1016/0006-291X(89)91700-2
De R, Sarkar S, Mazumder S et al (2018) Macrophage migration inhibitory factor regulates mitochondrial dynamics and cell growth of human cancer cell lines through CD74-NF-κB signaling. J Biol Chem 293:19740–19760. https://doi.org/10.1074/jbc.RA118.003935
Bordi M, Nazio F, Campello S (2017) The close interconnection between mitochondrial dynamics and mitophagy in cancer. Front Oncol 7:1–9. https://doi.org/10.3389/fonc.2017.00081
Xiao B, Deng X, Zhou W, Tan EK (2016) Flow cytometry-based assessment of mitophagy using mitotracker. Front Cell Neurosci 10:1–4. https://doi.org/10.3389/fncel.2016.00076
Song IS (2015) Mitochondria as therapeutic targets for cancer stem cells. World J Stem Cells 7:418. https://doi.org/10.4252/wjsc.v7.i2.418
Parte SC, Batra SK, Kakar SS (2018) Characterization of stem cell and cancer stem cell populations in ovary and ovarian tumors. J Ovarian Res 11:1–16. https://doi.org/10.1186/s13048-018-0439-3
Akhter Z, Sharawat SK, Kumar V et al (2018) Aggressive serous epithelial ovarian cancer is potentially propagated by EpCAM + CD45 + phenotype. Oncogene. https://doi.org/10.1038/s41388-017-0106-y
Bhattacharya R, Mitra T, Ray Chaudhuri S, Roy SS (2018) Mesenchymal splice isoform of CD44 (CD44s) promotes EMT/invasion and imparts stem-like properties to ovarian cancer cells. J Cell Biochem 119:3373–3383. https://doi.org/10.1002/jcb.26504
Chen H, Chan DC (2017) Mitochondrial dynamics in regulating the unique phenotypes of cancer and stem cells. Cell Metab 26:39–48. https://doi.org/10.1016/j.cmet.2017.05.016
Cetinbas NM, Sudderth J, Harris RC et al (2016) Glucose-dependent anaplerosis in cancer cells is required for cellular redox balance in the absence of glutamine. Sci Rep 6:1–12. https://doi.org/10.1038/srep32606
Venneti S, Dunphy MP, Zhang H et al (2015) Glutamine-based PET imaging facilitates enhanced metabolic evaluation of gliomas in vivo. Sci Transl Med 7:1–10. https://doi.org/10.1126/scitranslmed.aaa1009
Pan M, Reid MA, Lowman XH et al (2016) Regional glutamine deficiency in tumours promotes dedifferentiation through inhibition of histone demethylation. Nat Cell Biol 18:1090–1101. https://doi.org/10.1038/ncb3410
Wise DR, Thompson CB (2010) Glutamine addiction: a new therapeutic target in cancer. Trends Biochem Sci 35:427–433. https://doi.org/10.1016/j.tibs.2010.05.003
Zacharias NM, McCullough C, Shanmugavelandy S et al (2017) Metabolic differences in glutamine utilization lead to metabolic vulnerabilities in prostate cancer. Sci Rep 7:1–11. https://doi.org/10.1038/s41598-017-16327-z
Zhu L, Ploessl K, Zhou R et al (2017) Metabolic imaging of glutamine in cancer. J Nucl Med 58:533–537. https://doi.org/10.2967/jnumed.116.182345
Sonveaux P, Végran F, Schroeder T et al (2008) Targeting lactate-fueled respiration selectively kills hypoxic tumor cells in mice. J Clin Invest 118:3930–3942. https://doi.org/10.1172/JCI36843
Trotta AP, Chipuk JE (2017) Mitochondrial dynamics as regulators of cancer biology. Cell Mol Life Sci 74:1999–2017. https://doi.org/10.1007/s00018-016-2451-3
Campello S, Scorrano L (2010) Mitochondrial shape changes: Orchestrating cell pathophysiology. EMBO Rep 11:678–684. https://doi.org/10.1038/embor.2010.115
Zhao RZ, Jiang S, Zhang L, Bin YuZ (2019) Mitochondrial electron transport chain, ROS generation and uncoupling (review). Int J Mol Med 44:3–15. https://doi.org/10.3892/ijmm.2019.4188
Kashatus JA, Nascimento A, Myers LJ et al (2015) Erk2 phosphorylation of Drp1 promotes mitochondrial fission and MAPK-driven tumor growth. Mol Cell 57:537–551. https://doi.org/10.1016/j.molcel.2015.01.002
Afanas’ev I (2011) Reactive oxygen species signaling in cancer: comparison with aging. Aging Dis 2:219–230
Yu T, Robotham JL, Yoon Y (2006) Increased production of reactive oxygen species in hyperglycemic conditions requires dynamic change of mitochondrial morphology. Proc Natl Acad Sci U S A 103:2653–2658. https://doi.org/10.1073/pnas.0511154103
Kong B, Tsuyoshi H, Orisaka M et al (2015) Mitochondrial dynamics regulating chemoresistance in gynecological cancers. Ann N Y Acad Sci 1350:1–16. https://doi.org/10.1111/nyas.12883
Kingnate C, Charoenkwan K, Kumfu S et al (2018) Possible roles of mitochondrial dynamics and the effects of pharmacological interventions in chemoresistant ovarian cancer. EBioMedicine 34:256–266. https://doi.org/10.1016/j.ebiom.2018.07.026
Lonergan T, Bavister B, Brenner C (2007) Mitochondria in stem cells. Mitochondrion 7:289–296. https://doi.org/10.1016/j.mito.2007.05.002
Liao J, Liu PP, Hou G et al (2017) Regulation of stem-like cancer cells by glutamine through β-catenin pathway mediated by redox signaling. Mol Cancer 16:1–13. https://doi.org/10.1186/s12943-017-0623-x
Li B, Cao Y, Meng G et al (2019) Targeting glutaminase 1 attenuates stemness properties in hepatocellular carcinoma by increasing reactive oxygen species and suppressing Wnt/beta-catenin pathway. EBioMedicine 39:239–254. https://doi.org/10.1016/j.ebiom.2018.11.063
Tran TQ, Hanse EA, Habowski AN et al (2020) α-Ketoglutarate attenuates Wnt signaling and drives differentiation in colorectal cancer. Nat Cancer 1:345–358. https://doi.org/10.1038/s43018-020-0035-5
Ju HQ, Lu YX, Chen DL et al (2016) Redox regulation of stem-like cells though the CD44v-xCT axis in colorectal cancer: mechanisms and therapeutic implications. Theranostics 6:1160–1175. https://doi.org/10.7150/thno.14848
Jin L, Alesi GN, Kang S (2016) Glutaminolysis as a target for cancer therapy. Oncogene 35:3619–3625. https://doi.org/10.1038/onc.2015.447
Leone RD, Zhao L, Englert JM et al (2019) Glutamine blockade induces divergent metabolic programs to overcome tumor immune evasion. Science 366:1013–1021. https://doi.org/10.1126/science.aav2588
Matés JM, Di Paola FJ, Campos-Sandoval JA et al (2020) Therapeutic targeting of glutaminolysis as an essential strategy to combat cancer. Semin Cell Dev Biol 98:34–43. https://doi.org/10.1016/j.semcdb.2019.05.012
Peiris-Pagès M, Bonuccelli G, Sotgia F, Lisanti MP (2018) Mitochondrial fission as a driver of stemness in tumor cells: mDIVI1 inhibits mitochondrial function, cell migration and cancer stem cell (CSC) signalling. Oncotarget 9(17):13254–13275
We thankfully acknowledge Mr. Sounak Bhattacharya (confocal microscopy), Mr. Tanmoy Dalui, & Mrs. Debalina Chakraborty (flow cytometry), Dr. E. Padmanaban (NMR spectroscopy), and Mr. T. Muruganandan (AFM) of Central Instrumentation Facility of IICB. Prof. Pijush K. Das (CSIR-IICB) and Dr. Partha Chakrabarti (CSIR-IICB) are gratefully acknowledged for their valuable suggestions in preparing the manuscript. We are also thankful to Prof. Susanta Roychoudhury and Dr. Damayanti Das Ghosh (both from Saroj Gupta Cancer Centre & Research Institute, Kolkata, India) for providing human patient tissue samples and also for their valuable suggestions. Technical assistance of Mr. Prabir Kumar Dey is acknowledged. Other members of SSR laboratory are acknowledged for their co-operation.
This work was supported by grants from Science and Engineering Research Board (SERB) project GAP-360 (EMR/2016/002578) and the Council of Scientific and Industrial Research (CSIR) in house projects.
Conflict of interest
The authors declare that they have no conflict of interest.
Ethical approval for animal studies
All animal experiments were approved by the institutional animal ethics committee (IAEC), CSIR-Indian Institute of Chemical Biology, India, (Registration no. 147/GO/ReBi/S/99/CPSCEA) following the guidelines of Committee for the Purpose of Control and Supervision of Experiments on Animals (CPCSEA), Govt. of India.
Ethical approval for human studies
The human patients' tissue samples were collected from Saroj Gupta Cancer Centre and Research Institute (SGCCRI), Kolkata, India with proper human ethics clearance from the Institutional Ethics Committee (approval number -IEC SGCCRI REF NO.- 16/2/2018/Non-Reg/SSR/3).
Consent to participate
Informed written consent was taken from the patients in accordance with the 1964 Helsinki declaration.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Below is the link to the electronic supplementary material.
About this article
Cite this article
Prasad, P., Ghosh, S. & Roy, S.S. Glutamine deficiency promotes stemness and chemoresistance in tumor cells through DRP1-induced mitochondrial fragmentation. Cell. Mol. Life Sci. (2021). https://doi.org/10.1007/s00018-021-03818-6
- Glutamine metabolism
- Tumor growth
- Mitochondrial fission